Number of males and female PPMS patients who provided at least one valid EDSS measurement in each 5 year period.

<p>Number of males and female PPMS patients who provided at least one valid EDSS measurement in each 5 year period.</p

Number of males and female PPMS patients who provided at least one valid EDSS measurement in each 5 year period.

<p>Number of males and female PPMS patients who provided at least one valid EDSS measurement in each 5 year period.</p

Demographics of patients with relapsing- remitting (RR) / secondary progressive (SP) and primary progressive (PP) MS at the initial visit recorded to the MSBase Registry.

<p>Data are shown as mean (+/- SD)</p><p>Demographics of patients with relapsing- remitting (RR) / secondary progressive (SP) and primary progressive (PP) MS at the initial visit recorded to the MSBase Registry.</p

Mean value of EDSS for men and women with primary progressive MS by number of years since initial EDSS.

<p>EDSS is shown as mean value ± SD. Disease duration was derived as the date of the visit at which the EDSS was determined minus the date of onset of MS symptoms. Red squares = females, blue circles = males.</p

Kaplan-Meier estimates of time to secondary progressive MS by sex.

<p>Kaplan-Meier estimates of time to secondary progressive MS by sex.</p

Number of male and female RRMS/SPMS patients who provided at least one valid EDSS measurement in each 5 year period.

<p>Number of male and female RRMS/SPMS patients who provided at least one valid EDSS measurement in each 5 year period.</p

Exposure to treatment with interferon β-1a SC thrice weekly.

<p>Numbers of patients treated with Rebif recorded within the MSBase registry (n = 4678) and stratified by time on treatment are shown. Red bar in year 1 indicates the proportion of patients in whom dose escalation was a planned procedure. TIW, three times weekly.</p

Discontinuation events.

<p>Data are presented as number of discontinuation events with annual probability of discontinuation stratified by recorded reasons for discontinuation. The events were recorded in all patients within the MSBase ever treated with Rebif. Escalations of treatment dosage planned as part of the treatment initiation protocol (i.e. occurring within the initial 6 months of treatment with Rebif 22 µg) were excluded.</p

Baseline demographic and clinical data in patients unmatched and matched by the propensity score.

<p>CIS, clinical isolated syndrome; EDSS, Expanded Disability Status Scale; MS, multiple sclerosis; PPMS, primary progressive multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; SD, standard deviation; SPMS, secondary progressive multiple sclerosis.</p

Kaplan-Meier plots for the proportion of patients free from clinical relapses.

<p>No statistically significant differences between the treatment dosages were observed. MRI, magnetic resonance imaging; TIW, three times weekly.</p